Compare · ABBV vs CLVR
ABBV vs CLVR
Side-by-side comparison of AbbVie Inc. (ABBV) and Clever Leaves Holdings Inc. (CLVR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and CLVR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $466.55B, about 9035.7x CLVR ($51.6M).
- ABBV has hit the wire 15 times in the past 4 weeks while CLVR has been quiet.
- ABBV has more recent analyst coverage (25 ratings vs 4 for CLVR).
- Company
- AbbVie Inc.
- Clever Leaves Holdings Inc.
- Price
- $264.35+0.10%
- $2.99+40.38%
- Market cap
- $466.55B
- $51.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- News (4w)
- 15
- 0
- Recent ratings
- 25
- 4
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Clever Leaves Holdings Inc.
Clever Leaves Holdings Inc. cultivates, extracts, manufactures, and commercializes pharmaceutical-grade cannabinoid products in Colombia, Portugal, Germany, the United States, and Canada. The company operates through two segments, Cannabinoid and Non-Cannabinoid. It also engages in the formulating, manufacturing, marketing, distributing, and selling of homeopathic and other natural remedies, wellness products, detoxification products, nutraceuticals, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors. Clever Leaves Holdings Inc. is based in New York, New York.
Latest ABBV
- AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026
- AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting
- Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications
- AbbVie and BioLabs University of Toronto Open Applications for AbbVie Biotech Innovators Award at Life Sciences Ontario Forum
- Allergan Aesthetics to Advance Scientific Dialogue on Skin Longevity, Aging Biology and Exosome Science at the 2026 Science of Skin Summit
- AbbVie Declares Quarterly Dividend
- AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine
- AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
- AbbVie Inc. filed SEC Form 8-K: Regulation FD Disclosure
- AbbVie Completes Acquisition of Apogee Therapeutics
Latest CLVR
- New insider Bcm Investimentos Fundo De Investimento Multimercado Credito Privado Investimento No Exterior claimed ownership of 322,234 shares (SEC Form 3)
- SEC Form SC 13D/A filed by Clever Leaves Holdings Inc. (Amendment)
- SEC Form 15-12G filed by Clever Leaves Holdings Inc.
- SEC Form SC 13D filed by Clever Leaves Holdings Inc.
- SEC Form EFFECT filed by Clever Leaves Holdings Inc.
- SEC Form S-8 POS filed by Clever Leaves Holdings Inc.
- SEC Form S-8 POS filed by Clever Leaves Holdings Inc.
- SEC Form S-8 POS filed by Clever Leaves Holdings Inc.
- SEC Form POS AM filed by Clever Leaves Holdings Inc.
- SEC Form 25 filed by Clever Leaves Holdings Inc.